We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical markets in 10 European countries that joined the European Union (EU) last year have been growing at a rate of 16.5 percent during the past five years, according to a new research report.
Drug giant Pfizer has signed a deal to acquire Idun Pharmaceuticals, a San Diego-based biopharmaceutical firm that owns more than 150 patents covering drug targets, new chemical entities, drug-screening assays, diagnostics and antibodies.
While drug usage is expected to increase after the Medicare prescription drug benefit starts in 2006, drug spending will continue its slowdown over the next decade partly because of lower drug prices, according to a new Centers for Medicare & Medicaid Services (CMS) study.
The pharmaceutical industry says it is regrettable that Senate sponsors of medical malpractice reform legislation have removed an earlier provision that would have shielded drugmakers from punitive damages if they followed all necessary FDA guidelines when seeking approval of their products.
Any pharmaceutical importation plan that fixes the terms of trade is equivalent to importing price controls, which could endanger the future of drug innovation and limit access to new drugs, according to the head of the Senate health panel.
The financial deals made between drugmakers and pharmaceutical benefit managers (PBMs) in Maine may soon become more transparent as the state moves closer to implementing its PBM disclosure law.
Illinois has joined a growing list of states who have sued multiple drugmakers for inflating drug prices by overstating the average wholesale prices (AWP) of their products under Medicaid and Medicare programs.
Illinois has become the latest state to sue multiple drugmakers for inflating drug prices by overstating the average wholesale prices (AWP) of their products under Medicaid and Medicare programs.
More light may soon shine on the financial deals made between drugmakers and pharmaceutical benefit managers (PBMs), as Maine moves closer to implementing its PBM disclosure law and a private consulting firm promises to bring more transparency to the PBM industry.
Mylan Laboratories has received FDA approval to market a generic version of Johnson & Johnson’s (J&J’s) pain patch Duragesic. The FDA also denied citizen’s petitions that had attempted to block generic entry to the Duragesic market.